Author

Markus Möbs

Humboldt-Universität zu BerlinORCID 0000-0002-1502-3032Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Genetics· 1 Systems Biology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:differential expression· 2 Organism:human· 2 Assay:bulk RNA-seq· 1 Research Focus:cell type annotation· 1 Research Focus:drug response / drug discovery· 1 Approach:experimental assay· 1 Research Focus:gene regulatory network inference· 1 Assay:proteomics· 1

Frequent Co-Authors

Amina HasanovićiD· 1 shared Anuar MakhmutiD· 1 shared Cédric Moris· 1 shared Damian Tobias RiekeiD· 1 shared David Horst· 1 shared Elena Ioana BraicuiD· 1 shared ELIANE TABEA TAUBEiD· 1 shared Emil Netz· 1 shared

Activity by Year

2025-2026 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 24 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperGenetics

Amina HasanovićORCID

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Copy number signatures in targeted gene panels associate with patient outcomes in routine clinical data

Emil Netz, Cédric Moris, Amina Hasanović, Markus Möbs, Thorsten Schlomm, Nikolaj Frost, Raphael Mohr, Sebastian Stintzing, Elena Ioana Braicu, Jalid Sehouli, Damian Tobias Rieke, Manuela Benary, David Horst, Frank P. B. Dubois

The paper shows that copy number signatures from targeted gene panels are clinically relevant and associated with patient outcomes in ovarian, pancreatic, and colorectal cancers.

bioRxiv · Sep 25, 2026 · PreprintGenetics

Deep spatial proteomics of ovarian cancer precursor lesions delineates early disease changes and cell-of-origin signatures

Anuar Makhmut, Mihnea Paul Dragomir, Sonja Fritzsche, Markus Möbs, Wolfgang Schmitt, ELIANE TABEA TAUBE, Fabian Coscia

This study uses spatial proteomics to analyze ovarian cancer precursor lesions, identifying early molecular changes and therapeutic targets.

bioRxiv · Mar 19, 2025 · PreprintSystems Biology